Please login to the form below

Not currently logged in
Email:
Password:

Addyi

This page shows the latest Addyi news and features for those working in and with pharma, biotech and healthcare.

Rare disease therapies head the ‘class of 2015’

Rare disease therapies head the ‘class of 2015’

for 'female Viagra' after the FDA backed Addyi (flibanserin) for hypoactive sexual desire disorder in women. ... South Korea. evolocumab. Repatha. hypercholesterolaemia. PCSK9 inhibitor. Amgen. EU. flibanserin. Addyi.

Latest news

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    This month the deal was the purchase of Sprout Pharmaceuticals for $1bn cash in two instalments of $500m bringing the recently approved product Addyi (flibanserin) which is used for hypoactive sexual

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...
Precision medicine at Blue Latitude Health
At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...
Understanding the evolving CAR-T market
In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...

Infographics